Cargando…
The Potential of panHER Inhibition in Cancer
Purpose: Hyper-activation of the HER (erbB) family receptors, HER 1-4, leads to up-regulation of the three vital signaling pathways: mitogen activated protein kinase, phosphoinositide 3-kinase/AKT, and Janus kinase/signal transducer and activator of transcription pathways. Blocking HER1/EGFR has a l...
Autores principales: | Wang, Xiaochun, Batty, Kathleen M., Crowe, Philip J., Goldstein, David, Yang, Jia-Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309158/ https://www.ncbi.nlm.nih.gov/pubmed/25674538 http://dx.doi.org/10.3389/fonc.2015.00002 |
Ejemplares similares
-
Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
por: Wang, Xiaochun, et al.
Publicado: (2016) -
PANHER study: a 20-year treatment outcome analysis from a multicentre
observational study of HER2-positive advanced breast cancer patients from the
real-world setting
por: Pizzuti, Laura, et al.
Publicado: (2021) -
Machine Learning-Based Comparative Analysis of Pan-Cancer and Pan-Normal Tissues Identifies Pan-Cancer Tissue-Enriched circRNAs Related to Cancer Mutations as Potential Exosomal Biomarkers
por: Wang, Xuezhu, et al.
Publicado: (2021) -
Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression
por: Chen, Xi, et al.
Publicado: (2022) -
FAIM2 is a potential pan-cancer biomarker for prognosis and immune infiltration
por: Cai, Jiayang, et al.
Publicado: (2022)